Opioid Lawsuit Targets Purdue Family and President as Defendants

Explosive allegations revealed in Massachusetts AG lawsuit.

Massachusetts is one of 36 states suing Purdue Pharma, maker of the addictive opioid pain medication OxyContin, for deceiving doctors and patients in the sale of the drug.

Yet the Massachusetts lawsuit is unique in that it is the first to sue not only Purdue Pharma, which is owned by the Sackler family, but also eight members of the Sackler family themselves who served on the Purdue Board or as company executives, including former Purdue President Richard Sackler. 

The case made news late last week when Massachusetts Superior Court Judge Janet Sanders granted a motion filed by a consortium of major news outlets, including Reuters, The Boston Globe, and The New York Times, to reveal large portions of the 274-page amended complaint that had been heavily redacted. Judge Sanders rejected Purdue’s argument that she should wait to see how a special master in charge of discovery handles similar arguments being made in federal court in Ohio, where a multidistrict litigation against Purdue on behalf of several other states, counties, cities, and tribes is playing out. 

The newly released portions of the Massachusetts Attorney General’s complaint contain many explosive allegations highlighting the degree to which the Sackler family defendants allegedly micromanaged the Purdue business, as well as the family’s rapacious greed and disregard for patient welfare. The following are some of the more notable allegations:

  • In 2009, Purdue hired McKinsey to help shape its message for selling OxyContin and overcome rising concerns about addiction and overdoses. Among the McKinsey recommendations Purdue allegedly adopted was an intense push in 2013 to have its sales representatives increase their sales visits to high-prescribing doctors. McKinsey recommended that targeting the most frequent prescribers could boost OxyContin sales by hundreds of millions of dollars. As quotas rose, the complaint alleges, so did the total visits.      
         
  • “Purdue Pharma created the epidemic and profited from it through a web of illegal deceit. First, Purdue deceived Massachusetts doctors and patients to get more and more patients on its dangerous drugs. Second, Purdue misled them to use higher and more dangerous doses. Third, Purdue deceived them to stay on the drugs for longer and more harmful periods of time. All the while, Purdue peddled falsehoods to keep patients away from safer alternatives. Even when Purdue knew people in Massachusetts were addicted and dying, Purdue treated doctors and their patients as targets to sell more drugs. At the top of Purdue, a small group of executives led the deception and pocketed millions of dollars.” -First Amended Complaint, Paragraph 2.
  • Purdue failed to act on information it had about doctors suspected of abusing or illegally prescribing OxyContin. In 2012, the complaint alleges, Purdue rejected one of its employee’s requests to its head of sales that Purdue notify health insurers about this list of suspect doctors, which was code-named “Project Zero.”
  • Both the Massachusetts lawsuit and the multidistrict litigation in federal court in Ohio are being played out in the context of a 2007 move in which Purdue pleaded guilty to a felony and agreed to stop mispresenting OxyContin’s addictive properties; two of its executives, former CEO Michael Friedman and former legal counsel Howard Udell, also pleaded guilty to a misdemeanor for misbranding OxyContin. In her amended complaint, Massachusetts Attorney General Maura Heeley notes that no Sackler family members pleaded guilty in 2007, and suggests instead that as a way of buying their loyalty and silence, Purdue paid Udell $6 million between 2008 and 2009 and paid Friedman $3 million in 2008.  

The Massachusetts case is in its early stages.  Purdue has filed a motion challenging Massachusetts as an appropriate jurisdiction for this action, which has yet to be heard. We will continue to monitor the cases against Purdue in both Massachusetts state court and Ohio federal court as they develop.     

Comment on this article

Facebook
Twitter
LinkedIn

Mary Inman, Esq.

Mary Inman is a partner and co-founder of Whistleblower Partners LLP, a law firm dedicated to representing whistleblowers under the various U.S. whistleblower reward programs. Mary and her colleagues have pioneered a series of successful whistleblower cases against prominent health insurers, hospitals, provider groups, and vendors under the False Claims Act alleging manipulation of the risk scores of Medicare Advantage patients. Mary is a recognized expert and frequent author, commentator, and speaker on frauds in the healthcare industry, particularly those exposed by whistleblowers. Mary is a member of the RACmonitor editorial board and a popular panelist on Monitor Monday.

Related Stories

Leave a Reply

Please log in to your account to comment on this article.

Featured Webcasts

The Cost of Ignoring Risk Adjustment: How HCCs Impact Revenue & Compliance

The Cost of Ignoring Risk Adjustment: How HCCs Impact Revenue & Compliance

Stop revenue leakage and boost hospital performance by mastering risk adjustment and HCCs. This essential webcast with expert Cheryl Ericson, RN, MS, CCDS, CDIP, will reveal how inaccurate patient acuity documentation leads to lost reimbursements through penalties from poor quality scores. Learn the critical differences between HCCs and traditional CCs/MCCs, adapt your CDI workflows, and ensure accurate payments in Medicare Advantage and value-based care models. Perfect for HIM leaders, coders, and CDI professionals.  Don’t miss this chance to protect your hospital’s revenue and reputation!

May 29, 2025
I050825

Mastering ICD-10-CM Coding for Diabetes and it’s Complications: Avoiding Denials & Ensuring Compliance

Struggling with ICD-10-CM coding for diabetes and complications? This expert-led webcast clarifies complex combination codes, documentation gaps, and sequencing rules to reduce denials and ensure compliance. Dr. Angela Comfort will provide actionable strategies to accurately link diabetes to complications, improve provider documentation, and optimize reimbursement—helping coders, CDI specialists, and HIM leaders minimize audit risks and strengthen revenue integrity. Don’t miss this chance to master diabetes coding with real-world case studies, key takeaways, and live Q&A!

May 8, 2025
2025 Coding Clinic Webcast Series

2025 ICD-10-CM/PCS Coding Clinic Update Webcast Series

Uncover critical guidance. HIM coding expert, Kay Piper, RHIA, CDIP, CCS, provides an interactive review on important information in each of the AHA’s 2025 ICD-10-CM/PCS Quarterly Coding Clinics in easy-to-access on-demand webcasts, available shortly after each official publication.

April 14, 2025

Trending News

Featured Webcasts

The Two-Midnight Rule: New Challenges, Proven Strategies

The Two-Midnight Rule: New Challenges, Proven Strategies

RACmonitor is proud to welcome back Dr. Ronald Hirsch, one of his most requested webcasts. In this highly anticipated session, Dr. Hirsch will break down the complex Two Midnight Rule Medicare regulations, translating them into clear, actionable guidance. He’ll walk you through the basics of the rule, offer expert interpretation, and apply the rule to real-world clinical scenarios—so you leave with greater clarity, confidence, and the tools to ensure compliance.

June 19, 2025
Open Door Forum Webcast Series

Open Door Forum Webcast Series

Bring your questions and join the conversation during this open forum series, live every Wednesday at 10 a.m. EST from June 11–July 30. Hosted by Chuck Buck, these fast-paced 30-minute sessions connect you directly with top healthcare experts tackling today’s most urgent compliance and policy issues.

June 11, 2025
Open Door Forum: The Changing Face of Addiction: Coding, Compliance & Care

Open Door Forum: The Changing Face of Addiction: Coding, Compliance & Care

Substance abuse is everywhere. It’s a complicated diagnosis with wide-ranging implications well beyond acute care. The face of addiction continues to change so it’s important to remember not just the addict but the spectrum of extended victims and the other social determinants and legal ramifications. Join John K. Hall, MD, JD, MBA, FCLM, FRCPC, for a critical Q&A on navigating substance abuse in 2025.  Register today and be a part of the conversation!

July 16, 2025

Trending News

Happy National Doctor’s Day! Learn how to get a complimentary webcast on ‘Decoding Social Admissions’ as a token of our heartfelt appreciation! Click here to learn more →

This Memorial Day, we honor those who gave all for our freedom. Take 20% off sitewide through May 31 with code MEMORIAL25 at checkout

CYBER WEEK IS HERE! Don’t miss your chance to get 20% off now until Dec. 2 with code CYBER24